Jiangsu Hengrui Sets Tenth Board Session with Director Changes and New INED

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has issued an update.

Jiangsu Hengrui Pharmaceuticals has initiated the formation of its tenth board session, proposing an eleven-member board comprising six executive directors, one non-executive director, and four independent non-executive directors, subject to shareholder approval at the 2025 annual general meeting. The company plans to re-elect most existing directors, including its employee representative director, while maintaining continuity in leadership and corporate governance.

Independent non-executive director Dong Jiahong will retire at the conclusion of the AGM and step down from all committee roles, with the board expressing thanks for his service and planning to appoint successors to his committee positions. To strengthen its independent oversight, the company proposes appointing Lou Liguang as a new independent non-executive director for the term of the tenth board session, signaling an orderly transition in its governance structure and sustained focus on regulatory compliance and board renewal.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company listed in Hong Kong that develops, manufactures, and markets prescription drugs. The group focuses on innovative therapeutics and operates through a board structure comprising executive, non-executive, and independent non-executive directors to oversee its strategic and governance framework.

Average Trading Volume: 2,705,632

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$426.3B

For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.